Key result
Intravenous melagatran administered for 4 to 6 days in patients with acute DVT achieved stable plasma concentrations and was well tolerated with no clinically significant bleeding.
Why the study?
Does intravenous melagatran provide safe and effective anticoagulation and thrombus regression compared to unfractionated heparin in patients with acute proximal DVT?
Population
48 patients with acute proximal deep vein thrombosis (DVT)
Comparison
Intravenous infusions of melagatran at low… vs Intravenous unfractionated heparin adjusted by…
Design
RCT, randomised
Follow-up
4 to 6 days
Authors
Loading...
IV melagatran offers stable, bleed-free anticoagulation in acute DVT; extends direct thrombin inhibitor data ahead of oral transition trials.
RCT (n=48)
randomised
Does intravenous melagatran provide safe and effective anticoagulation and thrombus regression compared to unfractionated heparin in patients with acute proximal DVT?
Intravenous melagatran achieves stable, dose-dependent anticoagulation and promotes thrombus regression safely in patients with acute proximal DVT.
Eriksson et al. (1999) conducted an RCT in acute proximal deep vein thrombosis (DVT) (n=48). Melagatran vs. Unfractionated heparin was evaluated on Pharmacokinetics, pharmacodynamics and safety. Intravenous melagatran administered for 4 to 6 days in patients with acute DVT achieved stable plasma concentrations and was well tolerated with no clinically significant bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: